Figure 4
From: Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo
(A) Ratio of the percentage of CD89+ overall white blood cells and the percentage of CD16 + CD56+ overall white blood cells (NK cells) in healthy controls and in patients with melanoma or vitiligo, (B) Ratio of the percentage of granulocytes and the percentage of lymphocytes in healthy controls and in patients with melanoma or vitiligo. Red squares represent melanoma patients with metastatic disease, while brighter red squares with borders represent melanoma patients without metastases.